Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Summary Marketline's StemCells, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by StemCells, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and i...
Athersys Names Ivor Macleod Chief Financial Officer Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team. Mr. Macleod has been appointed Chief Financial Officer, effective as of January 31, 2020, to help plan and execute the financial strategy through potential product c...
Athersys Provides Update on One-Year ARDS Study Data One-year results support positive 28-day findings and suggest further benefits for ARDS patients CLEVELAND, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the one-year follow-up summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). Participants in the MUST-ARDS study were evaluated through 28 days for the primary clinical assessment and further assessed through...
Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan CLEVELAND, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that its collaborator in Japan, HEALIOS K.K. (“Healios”) received notification this week from the Pharmaceutical Affairs and Food Sanitation Council (“PAFSC”) that its acute respiratory distress syndrome (“ARDS”) clinical program using HLCM051 (MultiStem® Cell Therapy), will receive the orphan ...
Athersys Reports Third Quarter 2019 Results Management to host conference call at 4:30 pm ET today CLEVELAND, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2019. Highlights of the third quarter of 2019 and recent events include: Steady advancement of both MultiStem® ischemic stroke clinical trials, including the HEALIOS K.K. ("Healios") TREASURE study in Japan and in our Phase 3 registrational study MASTERS-2;Continued support for the Healios' acute respiratory distress syndrome ("ARDS") t...
Athersys to Host Third Quarter Financial Results Call CLEVELAND, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: DateNovember 6, 2019Time4:30 p.m. (Eastern Time)Telephone access: US and Canada(877) 396-3286Telephone access: International(647) 689-5528Conference ID:4183148Live webcast under Inve...
Athersys to Present at 2019 Cell & Gene Meeting on the Mesa Conference being held October 2nd- 4th, 2019 in Carlsbad; live video webcast available CLEVELAND, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2nd -4th in Carlsbad, California. Dr. Van Bokkelen will provide a brief overview of the Company’s mission and its therapeutic platform, MultiStem® cell therapy. The presentation will include information on the critical care indi...
Athersys Reports Second Quarter 2019 Results Management to host conference call at 4:30 pm EDT today CLEVELAND, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2019. Highlights of the second quarter of 2019 and recent events include: Received Fast Track designation from the FDA for our clinical development program involving administration of MultiStem® cell therapy for treatment of acute respiratory distress syndrome (“ARDS”);Presented positive results from the MUST-ARDS study at the American...
Athersys to Host Second Quarter Financial Results Call CLEVELAND, July 08, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date August 7, 2019 Time 4:30 p.m. (Eastern Time) Telephone access: US and Canada (877) 396-3286 Telephone access: International (647) 689-5528 Encore Passcode (needed for the repla...
Athersys to Present at Jefferies 2019 Healthcare Conference Conference being held June 4-7, 2019 in New York City CLEVELAND, June 04, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van Bokkelen’s presentation will take place at 11 AM Eastern Time on June 7, 2019 and will focus on the Company’s mission and the clinical development of its MultiStem® cell therapy. The talk will also summarize the recent positive da...
Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference Company taking active role with two podium presentations, panel participation and session chair CLEVELAND, May 28, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy (ISCT) conference taking place May 29 – June 2, 2019 in Melbourne, Australia. ISCT 2019 is the largest global translation-focused cell and gene therapy (CGT) meeting and is expected to draw delegates fr...
Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference The MultiStem® treatment group had more ventilator-free and ICU-free days, and greater reduction in acute inflammatory biomarkers compared to the placebo CLEVELAND, May 20, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from ...
Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome Dr. Geoff Bellingan to present the Phase 1/2 Acute Respiratory Distress Syndrome Data Next Week at the American Thoracic Society International Conference CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that its clinical program evaluating MultiStem® cell therapy for the treatment of Acute Respiratory Distress Syndrome (“ARDS”) has received Fast Track designation from the United States Food and Drug Administration (“FDA”). This import...
Athersys Reports First Quarter 2019 Results Management to host conference call at 4:30 pm EDT today CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of 2019 and recent events include: Announced positive results from our exploratory clinical study of MultiStem® cell therapy for treatment of acute respiratory distress syndrome ("MUST-ARDS"), showing reduced mortality and greater ventilator-free and ICU-free days in patients with moderate to severe ARD...
Athersys to Host Investor Day in New York City Special Event to be Held Tuesday, May 14, 2019 CLEVELAND, Ohio, April 15, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The event will focus on the Company’s mission, core capabilities and technologies, as well as progress made on developing its MultiStem® product platform and plans for the future. The investor day will include presentations from the Company’s management team as well as experts in the fields of stroke and ARDS. Dr. David Chiu, MD, ...
Athersys to Host First Quarter Financial Results Call CLEVELAND, April 10, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: DateMay 8, 2019Time4:30 p.m. (Eastern Time)Telephone access: US and Canada(877) 396-3286Telephone access: International(647) 689-5528Encore Passcode (needed for the replay only)6595362Li...
Athersys to Participate in Two Upcoming Healthcare Conferences CLEVELAND, April 01, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the Company’s participation in two upcoming biotechnology and healthcare conferences. On April 4th, Athersys will be part of the William Blair 3rd Annual Late-Stage Therapeutics Conference taking place in New York City. This event consists of panel discussions focused on healthcare issues specific to companies in Phase 3 clinical development or in the early stages of launching a new therapy. In addition, companies will conduct one-on-on...
Athersys to Host Year-End 2018 Financial Results Call CLEVELAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, William (B.J.) Lehmann, President and Chief Operating Officer, and Laura Campbell, Senior Vice President of Finance, will host the call as follows: DateMarch 14, 2019Time4:30 p.m. (Eastern Time)T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.